A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and therapeutic equivalence of a generic
tazarotene foam 0.1% and the reference listed Fabior™ (tazarotene foam, 0.1%) in the
treatment of acne vulgaris.